Phio Pharmaceuticals’ (PHIO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Phio Pharmaceuticals (NASDAQ:PHIO) in a report published on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.47) EPS and FY2027 earnings at ($0.77) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Price Performance

Phio Pharmaceuticals stock opened at $1.13 on Wednesday. The firm has a 50-day moving average of $1.05 and a 200-day moving average of $1.13. Phio Pharmaceuticals has a one year low of $0.81 and a one year high of $4.19. The company has a market cap of $13.13 million, a price-to-earnings ratio of -0.88 and a beta of 0.82.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.36). As a group, sell-side analysts expect that Phio Pharmaceuticals will post -1.45 earnings per share for the current year.

Institutional Investors Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its stake in Phio Pharmaceuticals stock. Cetera Investment Advisers grew its position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,500 shares of the company’s stock after purchasing an additional 9,000 shares during the quarter. Cetera Investment Advisers owned about 0.39% of Phio Pharmaceuticals worth $45,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical?stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next?generation RNAi compounds with potential applications in oncology and immuno?oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double?stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.